Lanifibranor is a pan-PPAR agonist oral drug in Phase 3 (NATiV3 trial) for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), a chronic liver disease affecting millions. Inventiva is a single-asset biotech whose entire valuation hinges on this one readout — topline results are expected in Q4 2026. Phase 2b data (NEJM-published) showed statistically significant improvements in both MASH resolution and fibrosis reduction at 24 weeks, earning FDA Breakthrough Therapy designation. The MASH market is projected at $25-32B by 2032-33, and the only approved oral competitor is Madrigal's Rezdiffra (launched 2024, $350M H1 2025 sales). Analyst consensus is Strong Buy with a mean price target ~$15.13 (287% upside), but the stock's low price reflects real binary risk: a trial miss would be catastrophic.
AX-0810 is ProQR Therapeutics' lead RNA editing candidate and the first clinical asset from its proprietary Axiomer™ platform. It targets NTCP to treat cholestatic liver diseases like biliary atresia (BA) and primary sclerosing cholangitis. Phase 1 data announced June 25, 2026, showed the platform works in humans for the first time — with dose-dependent target engagement, ~8-fold bile acid increases, and no safety signals. However, the stock is down significantly from its 52-week high ($3.10) and recently underwent a $59.2M dilutive equity offering. The company holds ~€81M cash and has a strong analyst consensus, but the next Phase 2 catalyst is 12+ months away.
Datroway (datopotamab deruxtecan) is a TROP2-directed antibody-drug conjugate (ADC) jointly developed and commercialized by AstraZeneca (AZN) and Daiichi Sankyo. It received its first US FDA approval in January 2025 for HR+/HER2- breast cancer, followed by accelerated approval for EGFR-mutated NSCLC in June 2025, and a third approval for first-line metastatic triple-negative breast cancer (TNBC) in May 2026. AstraZeneca has guided peak annual sales above $5 billion. In Daiichi Sankyo's FY2025 (ending March 2026), Datroway generated JPY 47.6 billion (~$315M) in global product sales, treating over 4,900 patients. At ESMO 2025, Datroway showed a slight efficacy and convenience edge over Gilead's competing TROP2 ADC, Trodelvy. The key risk is that as a megacap pharma with an $80B annual revenue target, Datroway is a single growth driver among many — positive news moves the stock only modestly.
Evomela (melphalan for injection) is CASI Pharmaceuticals' only commercialized product, approved in the US since 2016 and in China since 2018. It is a reformulated version of the decades-old chemotherapy melphalan, used as a conditioning agent before stem cell transplants in multiple myeloma. CASI holds exclusive rights to commercialize Evomela in Greater China under a license originally granted by Spectrum Pharmaceuticals (later assigned to Acrotech Biopharma). The drug faces severe headwinds: a domestic generic melphalan competitor in China has eroded sales, driving revenue from $28.5M (2024) to $20.7M (2025). A license-termination dispute with Acrotech was settled in June 2026, preserving CASI's rights but adding minimum purchase commitments. CASI was delisted from Nasdaq in February 2026 (now OTC: CASIF) and has warned of substantial doubt about its ability to continue as a going concern.
-
ORLADEYO (berotralstat) is BioCryst Pharmaceuticals' flagship product and the only FDA-approved once-daily oral prophylactic for hereditary angioedema (HAE). First approved in December 2020 for patients 12+, it generated $601.8M in net revenue in 2025 (+38% YoY) and drove the company to its first full-year profit. A pediatric oral pellet formulation was approved in December 2025, expanding the addressable market. The drug faces competition from Takeda's injectable Takhzyro (more efficacious but less convenient) and newer injectable entrants, but ORLADEYO's oral convenience and growing payer adoption support continued share gains. The company guides for $625M-$645M in 2026 ORLADEYO revenue.
Explore drug → -
Navenibart (formerly STAR-0215) is BioCryst's late-stage pipeline candidate for hereditary angioedema (HAE) prophylaxis, acquired via the $700M Astria Therapeutics deal closed January 2026. It is a long-acting monoclonal antibody that blocks plasma kallikrein and could offer best-in-class dosing convenience — every 3 or 6 months via subcutaneous injection. Phase 1b/2 ALPHA-STAR data showed reduced attack frequency and severity with a favorable safety profile. The Phase 3 ALPHA-ORBIT pivotal trial enrolled its last patient in June 2026, with topline data expected Q3 2027. BioCryst already commercializes ORLADEYO (an oral daily HAE drug generating ~$625-645M in 2026 revenue), providing an existing HAE commercial infrastructure and non-dilutive capital from a European licensing deal ($70M upfront, up to $275M milestones). However, the HAE prophylaxis market is increasingly crowded (Takeda's Takhzyro, Ionis' newly approved Dawnzera/donidalorsen, CSL's Haegarda), and navenibart faces a long wait for its pivotal readout.
Explore drug →
Surabgene lomparvovec (sura-vec, ABBV-RGX-314) is REGENXBIO's lead gene therapy candidate, developed in collaboration with AbbVie, for wet age-related macular degeneration (AMD) and diabetic retinopathy — two of the largest retinal disease markets. It aims to turn a chronic, injection-heavy treatment regimen into a one-time therapy. Phase 3 pivotal trials in wet AMD are fully enrolled with topline data in Q4 2026, while a Phase IIb/III diabetic retinopathy trial just began dosing. The drug faces competition from other gene therapies (Lilly's acquired ixo-vec from Adverum, 4DMT's 4D-150) but has AbbVie's commercial muscle and a two-delivery-route strategy. Analyst consensus is bullish (11 Buy, 2 Hold) with a mean price target of $24.36, implying ~83% upside from ~$13.28.
Envudeucitinib is Alumis Inc.'s lead asset — a next-generation oral TYK2 inhibitor in development for plaque psoriasis and systemic lupus erythematosus (SLE). Phase 3 ONWARD trials in psoriasis met all endpoints with high statistical significance: ~65% of patients achieved PASI 90 (90% skin clearance) and >40% achieved complete clearance (PASI 100) at week 24. The company plans an NDA submission in Q4 2026 and has a Phase 2b SLE readout due in Q3 2026. Alumis raised $345M in January 2026, ending Q1 with $569.5M cash — enough into Q4 2027. The stock trades at ~$26, up from a ~$3 low, but analyst consensus is Strong Buy with a $40 mean target (~60% upside). Key risks include competition from Takeda's similarly positioned TYK2 inhibitor zasocitinib and the binary nature of the upcoming SLE data.
ALN1003 is Alaunos Therapeutics' only pipeline candidate — an oral, non-hormonal small molecule in preclinical development for obesity and metabolic disorders. Early mouse studies show promising weight loss and metabolic improvements, but the program is at its earliest stage (no IND, no human data). The company faces an existential cash crisis: only ~$0.354M as of March 31, 2026, with runway extending only into Q2 2026. With zero analyst buy ratings, a going-concern warning, and intense competition from well-capitalized GLP-1 players (Novo Nordisk, Eli Lilly, Amgen), ALN1003 is a high-risk, long-shot preclinical asset at a company fighting for survival.
GT-02287 is Gain Therapeutics' only clinical-stage asset — a first-in-class oral GCase chaperone for Parkinson's disease, particularly in patients with GBA1 gene mutations (the largest known genetic risk factor for Parkinson's). Phase 1b data showed encouraging biomarker and clinical signals (81% reduction in CSF GluSph, stable MDS-UPDRS scores) in a small open-label study. The FDA just cleared the IND for a Phase 2a trial (June 29, 2026). However, the company faces severe financial constraints: $16.5M cash with a ~$4.7M/quarter burn rate and a going-concern warning. Analyst consensus is strongly bullish (10 of 11 analysts rate Buy/Strong Buy, mean target $7.20 vs ~$1.91), but Parkinson's is a notoriously tough indication where many promising drugs have failed, and the promising Phase 1b data came from just 21 patients in an open-label design.
DBV Technologies' VIASKIN Peanut Patch is an investigational epicutaneous immunotherapy (EPIT) patch for peanut allergy — a once-daily skin patch that desensitizes the immune system. After an FDA rejection in 2020 (Complete Response Letter citing patch adhesion concerns), DBV redesigned the patch and delivered two successful Phase 3 programs (EPITOPE in toddlers 1-3, VITESSE in children 4-7). The company is now preparing to resubmit a Biologics License Application (BLA) to the FDA for ages 4-7 in Q3 2026, with an accelerated approval pathway also secured for toddlers 1-3. The stock is essentially a single-asset bet on this approval. With a mean analyst price target of ~$40.85 (131% upside from ~$15.82), strong institutional holders (Baker Bros., Artisan Partners), and a large underserved market — but also significant cash burn, ATM dilution risk, and the lingering stain of the 2020 CRL — Viaskin represents a high-conviction, high-risk binary opportunity.
Fasedienol (PH94B) is Vistagen Therapeutics' lead asset — a first-in-class pherine nasal spray designed to quickly reduce social anxiety by targeting nose-to-brain neural circuits, without systemic absorption. After a positive Phase 3 PALISADE-2 readout in 2023 (stock surged ~1000%), two subsequent Phase 3 trials (PALISADE-3 in Dec 2025 and PALISADE-4 in June 2026) both failed to meet their primary endpoints. The stock lost ~70% on the PALISADE-4 miss. Vistagen plans to discuss a possible registrational path with the FDA using a new multi-dose trial design with a different primary endpoint (LSAS), but the drug's commercial prospects are materially impaired. The company has cash runway into 2027 but faces an uphill regulatory battle with an asset that has now failed twice in pivotal trials.
Annamycin (naxtarubicin) is Moleculin Biotech's lead drug candidate — a next-generation liposomal anthracycline being developed primarily for relapsed/refractory acute myeloid leukemia (AML). Its key selling point is a potentially clean cardiac safety profile, differentiating it from all currently approved anthracyclines whose use is capped by cumulative heart damage. On June 30, 2026, the company reported positive interim data from 45 patients in the pivotal MIRACLE trial showing a 3x higher complete remission rate (43% and 36% vs 12% control), but the data did not reach statistical significance in this small sample, causing the stock to drop ~25%. The full Part A data (~90 patients) is due in H2 2026 and will be the defining near-term catalyst. With cash runway only into Q3 2026 and a ~$17M market cap, this is a high-risk binary setup.
Rexlemestrocel-L (Revascor) is Mesoblast's lead cell therapy pipeline asset — an off-the-shelf, donor-derived mesenchymal precursor cell treatment for inflammatory and degenerative conditions. It is furthest along for end-stage heart failure (BLA filed June 30, 2026 with modular review) and chronic low back pain (Phase 3 enrollment complete, topline mid-2027). Mesoblast already has an FDA-approved commercial product (Ryoncil, approved Dec 2024) generating meaningful revenue, which de-risks the story versus typical pre-revenue biotechs. The stock has strong analyst support (9 analysts, mostly buy, $35 mean price target vs ~$14.38) and major insider buying. However, the DREAM-HF Phase 3 heart failure trial had mixed results (missed primary endpoint), the LVAD BLA timeline is uncertain, and the largest commercial opportunity (CLBP) won't read out for another ~12 months.
Tibulizumab (ZB-106) is a potential first-in-class bispecific antibody that simultaneously blocks two inflammatory pathways (IL-17A and BAFF), licensed by Zura Bio from Eli Lilly in 2023. It's Zura's lead and most valuable asset, currently in two Phase 2 trials: TibuSHIELD for hidradenitis suppurativa (topline data Q4 2026) and TibuSURE for systemic sclerosis (topline data H1 2027). Prior Phase 1 data showed good tolerability and target engagement. Zura has ~$225.6M cash funding operations into 2028, and analyst consensus is Strong Buy with a mean target of ~$15.67 (3x current price ~$5.17). The Q4 2026 HS readout is a make-or-break near-term catalyst.
Namodenoson (CF102) is Can-Fite BioPharma's lead oral drug candidate — a selective A3 adenosine receptor agonist being developed for liver cancer (HCC), MASH, and pancreatic cancer. The pivotal Phase 3 HCC LIVERATION trial is the primary value driver, with an estimated completion date of October 31, 2026 and results expected in H2 2026. The drug targets a specific high-unmet-need population (CPB7 cirrhosis patients with advanced HCC, largely excluded from other trials) and has FDA Fast Track, FDA Orphan Drug, and EMA Orphan Drug designations for HCC. A Phase 2a pancreatic cancer study met its safety endpoint in March 2026, fueling recent stock momentum. However, Can-Fite is a micro-cap with limited cash (~$5.5M), ongoing net losses, and a recent 1-for-3,000 reverse split — severe financing risk. The HCC competitive landscape is crowded, but Namodenoson's unique niche and oral formulation offer differentiation if Phase 3 data are positive.
-
Sabizabulin is an oral tubulin inhibitor that Veru Inc. originally developed for prostate cancer and then pivoted to COVID-19. After showing a striking 55% mortality reduction in a Phase 3 COVID trial, an FDA advisory committee voted 8-5 against emergency authorization in Nov 2022, effectively killing that program. The prostate cancer Phase 3 (VERACITY) was subsequently terminated. As of mid-2026, Veru has largely shelved sabizabulin, pivoted to cardiometabolic diseases, and is now exploring the drug as a preclinical anti-inflammatory agent for atherosclerosis. The company's valuation is now driven entirely by enobosarm. Sabizabulin has no near-term catalysts and is not investable as a standalone thesis.
Explore drug → -
Enobosarm is Veru Inc.'s lead drug candidate — an oral SARM repurposed into two sizable markets: obesity (as an add-on to GLP-1 drugs to preserve muscle) and AR+ breast cancer. The obesity angle gained significant traction after positive Phase 2b QUALITY data (Jan 2025), FDA regulatory clarity on endpoints (Sep 2025), and a high-profile clinical supply agreement with Novo Nordisk (June 2026) that sent VERU shares up ~167%. However, Veru has zero commercial revenue, disclosed going-concern risk, and filed a $21.8M ATM equity facility (July 2026) that could dilute existing holders by ~43%. The next major catalyst is the Phase 2b PLATEAU interim readout in Q1 2027, making this a high-conviction but binary single-asset biotech story.
Explore drug →
Paridiprubart (EB05) is Edesa Biotech's lead asset — a first-in-class anti-TLR4 monoclonal antibody for Acute Respiratory Distress Syndrome (ARDS), a life-threatening lung condition with no FDA-approved drug. In a Phase 3 trial across 278 patients, paridiprubart reduced 28-day mortality by 27% relative to placebo (p<0.001) and met all key secondary endpoints. The drug has FDA Fast Track and Breakthrough Therapy designations, and was selected by BARDA for a US government-funded platform trial. However, Edesa remains a pre-revenue clinical-stage micro-cap with ~$10M cash (as of March 2026), a ~$4M six-month burn rate, and a $150M shelf offering on file. The stock has already rerated sharply from $0.72 to the $5-11 range following the Phase 3 results. The next catalyst is regulatory engagement to define the filing pathway rather than a binary PDUFA date.
AMT-130 is uniQure's investigational one-time gene therapy for Huntington's disease (HD), a fatal genetic neurodegenerative disorder with no approved disease-modifying treatments. In September 2025, the company reported that high-dose AMT-130 slowed disease progression by 75% over 36 months on the primary endpoint (cUHDRS, p=0.003) versus external controls. After a regulatory rollercoaster — the FDA initially rejected the data package in late 2025, then reversed course in June 2026 — the agency now agrees the Phase 1/2 data can support an accelerated approval BLA. uniQure plans to submit in Q3 2026 and also pursue UK approval via the MHRA. With $586.6M in cash (runway into 2H 2029), the company is well-funded. Competition is limited — Skyhawk's oral SKY-0515 is in Phase 2/3 but years behind. Key risks: the Phase 1/2 used external rather than randomized controls, durability of effect beyond 3 years is unknown, and the gene therapy requires invasive brain surgery for administration.
-
TN-401 is an AAV9-based gene therapy from Tenaya Therapeutics (TNYA) for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), a genetic heart condition causing dangerous arrhythmias and sudden cardiac death. It is in a Phase 1b/2 dose-escalation trial (RIDGE-1) with encouraging early data: a mean 64% reduction in arrhythmia burden across 6 patients with no dose-limiting toxicities. TN-401 has FDA Orphan Drug and Fast Track designations. The main risk is direct competition from Rocket Pharmaceuticals' RP-A601 (same target, Phase 1, with RMAT designation) and the early stage of development. Tenaya has adequate cash into H2 2027 and a diversified pipeline led by TN-201 for hypertrophic cardiomyopathy. The stock trades near $0.79, far below the analyst mean target of $4.00, reflecting significant early-stage risk but also meaningful upside if TN-401 data continue positive.
Explore drug → -
TN-201 is Tenaya Therapeutics' lead asset — a one-time AAV9 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), the most common genetic form of the disease. Interim data from the Phase 1b/2 MyPEAK-1 trial have shown encouraging and durable signs of cardiac remodeling (reduced left ventricular wall thickness, improved mass index), biomarker improvements, and symptom reduction in all evaluable patients, with benefits sustained out to two years in the low-dose cohort. The drug has received FDA Fast Track, Orphan Drug, and Rare Pediatric Drug Designations, plus EMA PRIME designation. However, the dataset is very small (n=6 total dosed), the company has a history of a clinical hold (now resolved), and Tenaya has ~$80.9M in cash funding operations into H2 2027. No approved therapy currently addresses the genetic cause of MYBPC3-HCM, positioning TN-201 as a potential first-in-class disease-modifying treatment if it succeeds in larger trials.
Explore drug →
-
ELI-008 is a preclinical cancer vaccine from Elicio Therapeutics (Nasdaq: ELTX) that targets p53 gene mutations found broadly across solid tumors. It uses the company's AMP lymph node-targeting platform to stimulate an immune response. While preclinical data at AACR 2024 showed it can induce strong T-cell responses in animal models, ELI-008 has not entered clinical trials, has no IND filed, and its advancement is contingent on funding the company does not currently have. Elicio is in a precarious position: its lead drug ELI-002 failed a Phase 2 pancreatic cancer study in June 2026, the stock lost ~47-72.5% of its value in a single session, and the company had to raise $15M in a dilutive offering (~20% dilution at $3.43/share) just to keep its lead program alive. ELI-008 is negligible optionality for investors — far from any value-driving catalyst.
Explore drug → -
ELI-002 is Elicio Therapeutics' lead and only clinical-stage asset — a therapeutic cancer vaccine targeting KRAS-mutant tumors. It showed promising Phase 1 results (published in Nature Medicine) with 84% of patients mounting T-cell responses that correlated with improved survival. However, the pivotal Phase 2 AMPLIFY-7P trial in adjuvant pancreatic cancer missed its primary endpoint of disease-free survival in June 2026, sending shares down 47-72%. Post-hoc analyses suggest benefit in patients with lower residual disease, and rare complete responses were seen in 3 metastatic patients when combined with checkpoint inhibitors. The company is now pursuing a refined Phase 3 strategy while facing a cash runway through Q4 2026 (at best) and having just raised $15M in a dilutive offering at $3.43/share. Analysts remain bullish (7 Buy, 1 Hold) with a mean price target of $20.67 representing ~300% upside from recent levels, but the stock carries extreme risk given the Phase 2 failure, single-asset pipeline, and precarious finances.
Explore drug →
Daraxonrasib (RMC-6236) is Revolution Medicines' lead asset — an oral, pan-RAS inhibitor that just delivered what analysts and doctors are calling "unprecedented" Phase 3 results in metastatic pancreatic cancer, nearly doubling median overall survival vs chemotherapy (13.2 vs 6.7 months, HR 0.40). The FDA has granted Breakthrough Therapy, Orphan Drug, and a National Priority Voucher, signaling an accelerated regulatory path. Truist projects approval in 2L PDAC by end of Q3 2026. The stock has already rallied ~258% over the past 12 months on this success, and the defining binary event (Phase 3 readout) is behind it. The next catalyst is the NDA filing and FDA decision, but significant upside from current levels near the 52-week high may be limited until the broader pipeline (1L PDAC, NSCLC) matures.
ARCT-032 is Arcturus Therapeutics' lead pipeline asset — an inhaled mRNA therapy for cystic fibrosis (CF) targeting Class I mutation patients who cannot use existing CFTR modulator drugs like Vertex's Trikafta. The drug has FDA Orphan Drug and Rare Pediatric Disease designations. Interim 28-day Phase 2 data (Oct 2025) showed safety but no meaningful improvement in lung function (FEV1), causing the stock to drop ~50-56%. However, CT imaging showed mucus plug reduction in 4/6 patients. A longer 12-week Phase 2 study began enrollment in Q1 2026 with ~20 patients, and the company just signed a strategic Phase 3 partnership with Thermo Fisher (July 2026). The stock trades at ~$6.89 (market cap ~$196M) with analyst consensus of 9 Buy/4 Hold and mean price target ~$19.89 — implying large upside if the 12-week data shows lung function improvement.
Levosimendan is a well-characterized cardiovascular drug already approved in IV form in 60+ countries outside the US (branded Simdax by Orion) for acute decompensated heart failure. Tenax Therapeutics (TENX) is developing an oral formulation (TNX-103) for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) — a severe condition with zero FDA-approved therapies and a large unmet need. The Phase 3 LEVEL trial completed enrollment at ~230 patients and topline results are due in August 2026, with a late-breaking presentation at ESC Congress 2026. Analysts are overwhelmingly bullish (Strong Buy consensus, mean PT ~$33.88 vs ~$13.29), and major institutions (Janus Henderson, Point72, FMR, Adage Capital) have been accumulating shares. With $118.8M cash funding operations through Q1 2028, the company is well-capitalized into this binary catalyst.
-
CTX-8371 is a Phase 1 bispecific antibody from Compass Therapeutics that blocks both PD-1 and PD-L1 — an approach that differs from marketed checkpoint inhibitors. At ASCO 2026, it showed a 33% overall response rate (2 of 6 evaluable patients) at the two highest doses in patients whose cancers had already progressed on prior checkpoint inhibitors, with no dose-limiting toxicities. The company has opened TNBC and NSCLC expansion cohorts and expects additional data in Q4 2026. The stock crashed ~65% in April 2026 after the company's lead asset tovecimig missed its overall survival endpoint, leaving CTX-8371 as a potential upside catalyst. However, the asset is very early-stage in one of the most competitive oncology spaces in history, with >40 PD-1/L1 pipeline molecules and established blockbusters like Keytruda and Opdivo dominating.
Explore drug → -
Tovecimig (CTX-009) is Compass Therapeutics' lead drug candidate — a bispecific antibody that starves tumors by blocking two blood-vessel growth pathways (DLL4 and VEGF-A). In the Phase 2/3 COMPANION-002 trial for second-line biliary tract cancer (a rare, aggressive cancer with few treatment options), it met its primary endpoint (response rate) and showed a 56% reduction in disease progression risk. However, it failed to improve overall survival — a crucial metric — due to a high crossover rate that scrambled the data. The stock crashed 63% on that news in April 2026, falling from ~$5 to ~$1.84. The company now plans a pivotal FDA pre-BLA meeting in August 2026 to determine whether regulators will accept the data package for a BLA submission. The stock trades at ~$2.18 with a Strong Buy analyst consensus and ~304% implied upside, but the binary risk of the FDA meeting outcome makes this a high-stakes, asymmetric bet.
Explore drug →
Seralutinib is Gossamer Bio's only pipeline asset — an inhaled kinase inhibitor for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The pivotal Phase 3 PROSERA study announced February 23, 2026 narrowly missed its primary endpoint (13.3m improvement in 6-minute walk distance, p=0.032 vs pre-specified α of 0.025), triggering an ~80% single-day stock crash and a wave of analyst downgrades. Despite the miss, management completed a pre-NDA meeting with the FDA in mid-June 2026 and is targeting an NDA submission in September 2026, with potential approval in Q3 2027 if accepted. The company has restructured $181M in convertible debt (highly dilutive), cut ~50% of staff, and paused its second Phase 3 trial (SERANATA for PH-ILD). With the stock trading around $0.16, a market cap of ~$80M, and class-action lawsuits pending, seralutinib represents a deeply distressed, high-risk speculative play with a low-probability regulatory path forward.